PARIS (Reuters) – Bavarian Nordic shares jumped on Thursday as the Danish biotech company benefited from interest in its monkeypox vaccine after the World Health Organization declared the disease an international public health emergency.
On the Copenhagen Stock Exchange, at around 09:20 GMT, the share price rose 9.8% to 245 Danish crowns (32.84 euros), after having soared by around 17% in early trading, compared with a gain of 0.54% for the index at the same time.
The WHO declared a global emergency over the monkeypox outbreak on Wednesday, its highest level of alert, which can help speed up research, funding and measures to prevent the outbreak from spreading.
Bavarian Nordic has Jynneos in its product range, one of the few vaccines available against “mpox”.
“The vaccine (…) against monkeypox will be in demand, which is one of the main reasons for the significant increase in the share price in recent days,” said Per Hansen, an analyst at Nordnet.
The stock had already soared on Wednesday, with Bavarian Nordic announcing the day before that it had received an order from the European Emergency Preparedness and Response Authority for 175,420 doses of Jynneos.
Further orders of this magnitude could follow from individual organisations or countries, said Nordea analyst Michael Novod, adding that Bavarian’s underlying operations were performing extremely well.
(Written by Pauline Foret, with contributions from Elviira Luoma, edited by Augustin Turpin)
Copyright © 2024 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
